Research programme: cruzain inhibitors - ArQule

Drug Profile

Research programme: cruzain inhibitors - ArQule

Alternative Names: Cruzain inhibitors research programme - ArQule

Latest Information Update: 03 Jan 2001

Price : $50

At a glance

  • Originator ArQule
  • Class
  • Mechanism of Action Cysteine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Trypanosomiasis

Most Recent Events

  • 03 Jan 2001 Discontinued-Preclinical for Trypanosomiasis in USA (Unknown route)
  • 16 Sep 1999 New profile
  • 16 Sep 1999 Preclinical development for Trypanosomiasis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top